Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
TNF 7124 ADALIMUMAB CHEMBL1201580 inhibitor, antibody PharmGKB, TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 12044041, 11752352, 14532145, 15200343, 15022409, 15046527
TNF 7124 CLENBUTEROL CHEMBL49080 DrugBank 11193379, 17139543, 10071758, 16261833, 15021963
TNF 7124 VX-702 CHEMBL1090090 DrugBank
TNF 7124 APREMILAST CHEMBL514800 DrugBank
TNF 7124 BUPIVACAINE CHEMBL1098 NCI 15781526
TNF 7124 PROPYLTHIOURACIL CHEMBL1518 NCI 15119959
TNF 7124 RUTIN CHEMBL226335 NCI 12423426
TNF 7124 LENALIDOMIDE CHEMBL848 inhibitor ClearityFoundationClinicalTrial, TTD
TNF 7124 OZORALIZUMAB CHEMBL1743054 inhibitor TdgClinicalTrial, ChemblInteractions
TNF 7124 PEGSUNERCEPT CHEMBL1743057 inhibitor ChemblInteractions
TNF 7124 PRANLUKAST CHEMBL21333 DrugBank 17430359, 12801316, 12801315
TNF 7124 INAMRINONE CHEMBL12856 inhibitor DrugBank 1611705, 11969359, 10075051, 10444479, 11805217
TNF 7124 CARBAMAZEPINE CHEMBL108 PharmGKB, NCI 15565432
TNF 7124 GENTAMICIN CHEMBL3039597 NCI 14565862
TNF 7124 HYDROXYCHLOROQUINE CHEMBL1535 NCI 9002011
TNF 7124 MAGNESIUM SULFATE CHEMBL1200456 NCI 16384608
TNF 7124 SPIRONOLACTONE CHEMBL1393 NCI 16837769
TNF 7124 TIMOLOL MALEATE CHEMBL1200870 NCI 12219997
TNF 7124 NAFAMOSTAT CHEMBL273264 antibody TdgClinicalTrial, TTD
TNF 7124 TALACTOFERRIN ALFA CHEMBL2108651 inhibitor TTD
TNF 7124 DERSALAZINE CHEMBL2106406 TdgClinicalTrial
TNF 7124 VADIMEZAN CHEMBL71263 inducer TALC
TNF 7124 ETANERCEPT CHEMBL1201572 inhibitor, antibody PharmGKB, TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 10357816, 11752352, 10375846, 10338381, 10405518, 10206649
TNF 7124 INFLIXIMAB CHEMBL1201581 inhibitor, antibody PharmGKB, TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 16456024, 11752352, 15691217, 15804598, 12110154, 16622728, 16052578, 15691299, 15481318, 15674127, 17642244
TNF 7124 CHLOROQUINE CHEMBL76 DrugBank 16761500, 16670522, 17456179, 16870179, 16418198
TNF 7124 GLUCOSAMINE CHEMBL606759 DrugBank 16431966, 12244074, 16469053, 15930455, 16445576
TNF 7124 FOLIC ACID CHEMBL1622 NCI 14608078
TNF 7124 LACTULOSE HYDRATE CHEMBL1237068 NCI 11226652
TNF 7124 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 8615653
TNF 7124 CHEMBL219629 CHEMBL219629 inhibitor TTD
TNF 7124 PIRFENIDONE CHEMBL1256391 inhibitor TTD
TNF 7124 CELASTROL CHEMBL301982 TTD
TNF 7124 MILTEFOSINE CHEMBL125 NCI 7883777
TNF 7124 MIDAZOLAM CHEMBL655 NCI 16406030
TNF 7124 ORTATAXEL CHEMBL382300 inhibitor TTD
TNF 7124 NERELIMOMAB CHEMBL2108566 inhibitor ChemblInteractions
TNF 7124 ONERCEPT CHEMBL2107911 inhibitor ChemblInteractions
TNF 7124 AZ-9773 CHEMBL2109587 inhibitor ChemblInteractions
TNF 7124 THALIDOMIDE CHEMBL468 inhibitor TdgClinicalTrial, TEND, DrugBank, TTD 12046682, 12102294, 11752352, 8755512, 12167383, 12105857, 12113124
TNF 7124 IBUDILAST CHEMBL19449 DrugBank
TNF 7124 PLACULUMAB CHEMBL2108739 inhibitor TdgClinicalTrial, ChemblInteractions, DrugBank, TTD
TNF 7124 TALMAPIMOD CHEMBL514201 DrugBank
TNF 7124 CHEMBL173373 CHEMBL173373 DrugBank
TNF 7124 POMALIDOMIDE CHEMBL43452 inhibitor DrugBank 22917017
TNF 7124 PROCARBAZINE CHEMBL1321 NCI 12230110
TNF 7124 PYRIDOXINE CHEMBL1364 NCI 16277693
TNF 7124 RISPERIDONE CHEMBL85 NCI 11545247, 15567770
TNF 7124 CROMOLYN SODIUM CHEMBL74 NCI 7554404
TNF 7124 URAPIDIL CHEMBL279229 inhibitor TdgClinicalTrial, TTD
TNF 7124 DELMITIDE CHEMBL2108587 inhibitor TTD
TNF 7124 PF-04236921 CHEMBL2109613 TdgClinicalTrial
TNF 7124 AJULEMIC ACID CHEMBL456341 inhibitor TTD
TNF 7124 PENTOXIFYLLINE CHEMBL628 antibody TTD
TNF 7124 ABACAVIR CHEMBL1380 PharmGKB
TNF 7124 METHIMAZOLE CHEMBL1515 NCI 8491516
TNF 7124 LENERCEPT CHEMBL2108208 inhibitor ChemblInteractions
TNF 7124 FLUOCINOLONE ACETONIDE CHEMBL989 NCI 16454812
TNF 7124 GLIMEPIRIDE CHEMBL1481 NCI 14686960
TNF 7124 HALOFUGINONE CHEMBL1197091 NCI 16769768
TNF 7124 NORDIHYDROGUAIARETIC ACID CHEMBL52 NCI 15379894
TNF 7124 OMEPRAZOLE CHEMBL1503 NCI 16815316
TNF 7124 CERTOLIZUMAB PEGOL CHEMBL1201831 inhibitor, antibody, neutralizer TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 23620660
TNF 7124 BETA-LAPACHONE CHEMBL15192 NCI 10075082
TNF 7124 PRAZOSIN HYDROCHLORIDE CHEMBL1558 NCI 11406472
TNF 7124 GOLIMUMAB CHEMBL1201833 inhibitor, antibody TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 21079302
TNF 7124 CEFOTAXIME CHEMBL1730 NCI 10989981, 8354907
TNF 7124 MIDOSTAURIN CHEMBL608533 NCI 15914319
TNF 7124 RABEPRAZOLE CHEMBL1219 NCI 16815316
TNF 7124 AFELIMOMAB CHEMBL2108887 inhibitor ChemblInteractions, DrugBank 10829362
TNF 7124 DIDANOSINE CHEMBL1460 NCI 9430255
TNF 7124 PENICILLIN G SODIUM CHEMBL1126 NCI 1375873
TNF 7124 MEROPENEM CHEMBL127 NCI 8354907

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
TNF rs1800629 A adalimumab efficacy yes Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. 19365401 699638591
TNF rs1800629 A etanercept efficacy yes Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. 16909270 1451243060
TNF rs1800629 GG infliximab efficacy yes Patients with the GG genotype had a significantly greater decrease in the Disease Activity Score in 28 joints (DAS28) score as compared to those with the AG genotype (no patients with the AA genotype were present in the cohort) after a mean of 24.8 months of treatment. The authors also noted a tendency of a better Health Assessment Questionnaire (HAQ) evolution (p=0.064), but no significant difference in radiological outcome (Sharp score). Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG. 15834068 1444668415
TNF rs1800629 GG adalimumab efficacy yes Response assessed after 24 weeks of treatment using the modified disease activity score (DAS28). Good response was a DAS28 improvement of >2.2 from baseline, moderate response an improvement of >=1.2 and <=2.2, and non-response as an improvement of <1.2. Patients with the GG genotype had the largest improvement in DAS28 score (2.72 +/- 0.70), following by those with the AG genotype (1.5 +/- 0.16) then those with the AA genotype (0.83 +/- 0.15). There was a significant difference in DAS28 improvement score between all genotypes. Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 16720636 1444668429
TNF rs1800629 A infliximab efficacy no No significant differences in the frequency of the alleles or genotypes were seen between responders and non-responders to infliximab treatment. Patients had either active luminal (non-fistulizing) disease (n=133) or fistulizing disease (n=87). In patients with luminal disease, responders were defined as those who had a decrease of Crohn disease activity index (CDAI) of below 150 ("complete response") or a decrease of 70 points in CDAI ("partial response") after 4 weeks. In patients with fistulizing disease, responders were defined as complete fistulas healing ("complete response") or decrease in 50% of the number of draining fistulas ("partial response") at two consecutive visits. Allele A is not associated with response to infliximab in people with Crohn Disease as compared to allele G. 12190096 1444668038
TNF rs1800629 AG + GG infliximab efficacy no No significant difference in change in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment was seen between the two genotypes. Linear regression analysis performed, adjusted for baseline DAS28, among other factors. Additionally, there was no significant difference in genotype frequency between those who were "good" responders according to EULAR criteria, and those who were "non-responders". Genotypes AG + GG is not associated with response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AA. 18713756 1444668735
TNF rs1800629 GG adalimumab efficacy yes When in a haplotype with rs1799724 and rs361525. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate. Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid. 17673491 1444693800
TNF rs1799724 CT + TT lansoprazole efficacy no No significant difference in the percentage of patients who failed Helicobacter pylori (H. pylori) treatment were seen between the two genotype groups. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Genotypes CT + TT are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype CC. 16815316 1183680059
TNF rs1799724 TT Tumor necrosis factor alpha efficacy yes At week 24 of treatment, DAS28 was significantly lower in those with the TT genotype as compared to those who carried the C allele, although there was no significant difference in the remission rate. Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CC + CT. 25311255 1445585209
TNF rs1799724 CT + TT etanercept efficacy yes Clinical efficacy assessed by percentage improvements (20, 50 or 70%) in disease activity according to the American College of Rheumatology (ACR) criteria at 12 weeks (i.e. ACR20, ACR50, ACR70). Patients who were ACR20 non-responders were compared against patients who were ACR70 responders. p-value adjusted for Korea Health Assessment Questionnaire (KHAQ) score at start of study and Patient's global assessment score at start of study. Please note that the p-value corrected for multiple testing (Bonferroni) is no longer significant (p=0.34). Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC. 15695296 1444668324
TNF rs1799724 CC adalimumab efficacy yes When in a haplotype with rs1800629 and rs361525. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate. Genotype CC is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid. 17673491 1444693787
TNF rs1799724 CC rituximab efficacy no No significant association was seen between genotype and whether a patient was a "responder" or a "non-responder". "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Please note alleles have been complemented to the plus chromosomal strand. Genotype CC is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT. 22129793 982047094
TNF rs1800630 AA infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype AA is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AC + CC. 22960943 1183689667
TNF rs3093548 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CT + TT. 22960943 1183689695
TNF rs4248163 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CG + GG. 22960943 1183689699
TNF rs55994001 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CT + TT. 22960943 1183689703
TNF rs55634887 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689707
TNF rs2736195 AA infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype AA is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AG + GG. 22960943 1183689687
TNF rs4248159 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AC. 22960943 1183689683
TNF rs4248160 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689691
TNF rs4647198 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CT + TT. 22960943 1183689663
TNF rs361525 AG Tumor necrosis factor alpha efficacy no No significant difference in the frequency of the genotypes was seen between patients who were classified as "good responders" and those who were classified as "poor and nonresponders". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.43). Genotype AG is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotype GG. 23057546 1444687084
TNF rs1799964 C etanercept efficacy no No significant difference in the frequency of the alleles was seen when comparing responders to non-responders, when using 1) American College of Rheumatology (ACR)20 criteria, 2) ACR70 criteria or 3) ACR20 criteria non-responders vs ACR70 criteria responders at 12 weeks of treatment. Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele T. 15695296 1444668343
TNF rs1800630 C etanercept efficacy no No significant difference in the frequency of the alleles was seen when comparing responders to non-responders, when using 1) American College of Rheumatology (ACR)20 criteria, 2) ACR70 criteria or 3) ACR20 criteria non-responders vs ACR70 criteria responders at 12 weeks of treatment. Allele C is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele A. 15695296 1444668354
TNF rs361525 A etanercept efficacy no No significant difference in the frequency of the alleles was seen when comparing responders to non-responders, when using 1) American College of Rheumatology (ACR)20 criteria, 2) ACR70 criteria or 3) ACR20 criteria non-responders vs ACR70 criteria responders at 12 weeks of treatment. Allele A is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to allele G. 15695296 1444668370
TNF rs1800629 G Tumor necrosis factor alpha efficacy yes Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A. 26244882 1447680222
TNF rs1799724 C Tumor necrosis factor alpha efficacy yes Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele T. 26244882 1447680253
TNF rs361525 G Tumor necrosis factor alpha efficacy yes Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele A. 26244882 1447680238
TNF rs1800629 A sirolimus metabolism/PK no No significant difference in log-transformed dose-adjusted trough concentrations (C/D) were seen between the genotypes AA, AG or GG. Allele A is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to allele G. 22094953 1448567951
TNF rs1800629 GG Tumor necrosis factor alpha efficacy yes A meta-analysis of 5 studies: in 3 studies patients were treated with just infliximab (one study not included in the genotype association analysis), in one study in patients were treated with infliximab + adalimumab + etanercept, and in one study infliximab + rhTNFR-Fc. Patients with inflammatory diseases; Crohn's disease, Ankylosing spondylitis, Psoriatic arthritis, psoriasis. Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG. 24192118 1183689326
TNF rs1800750 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689711
TNF rs361525 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689719
TNF rs361525 GG adalimumab efficacy no No significant difference in genotype frequencies was seen between those who were responders to treatment and those who were non-responders. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Genotype GG is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 17673491 1444693781
TNF rs361525 GG infliximab efficacy yes Patients with the GG genotype were also more frequent in the group classified as having a "good" response according to the EULAR criteria, as compared to those with the AG genotype. Additionally, patients with the GG genotype had a greater decrease in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment, as compared to those with the AG genotype, but this was not significant in univariate linear regression analysis, adjusted for baseline DAS28, among other factors. No patients with the AA genotype present in the population. Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG. 18713756 1444668751
TNF rs361525 GG adalimumab efficacy yes When in a haplotype with rs1800629 and rs1799724. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Those homozygous for the GGC (rs361525-rs1800629-rs1799724) haplotype had a significantly lower ACR50 response rate as compared to subjects with any other diplotype (see paper for diplotypes present in population). This effect was more important in a subgroup of patients receiving concomitant methotrexate. Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid. 17673491 1444693810
TNF rs361525 AG etanercept efficacy no No significant difference in change in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment was seen between the two genotypes. Linear regression analysis performed, adjusted for baseline DAS28, among other factors. Additionally, there was no significant difference in genotype frequency between those who were "good" responders according to EULAR criteria, and those who were "non-responders". No patients with the AA genotype present in the population. Genotype AG is not associated with response to etanercept in people with Arthritis, Rheumatoid as compared to genotype GG. 18713756 1444668744
TNF rs1799724 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CT + TT. 22960943 1183689671
TNF rs1799724 CC adalimumab efficacy no No significant difference in genotype frequencies was seen between those who were responders to treatment and those who were non-responders. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Genotype CC is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT. 17673491 1444693768
TNF rs1799724 CC Tumor necrosis factor alpha efficacy yes The frequency of the CC genotype was higher in those patients who were "good responders" to anti-TNF therapy, as compared to those who were "poor and nonresponders". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Please note that the T allele was significantly more frequent in those with ankylosing spondylitis as compared to healthy controls (p = 2.455 x 10^-7). Additionally, note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.20). Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CT + TT. 23057546 1444687098
TNF rs1799724 CC Tumor necrosis factor alpha efficacy yes A meta-analysis of 3 studies: in 1 study patients were treated with just infliximab (this study was not included in the genotype association analysis), in 1 study patients were treated with infliximab + adalimumab + etanercept, and in one study infliximab + rhTNFR-Fc. Patients with inflammatory diseases; Crohn's disease, Ankylosing spondylitis, psoriasis. Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes CT + TT. 24192118 1183689377
TNF rs1799964 TT infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype TT is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CC + CT. 22960943 1183689659
TNF rs1799964 TT Tumor necrosis factor alpha efficacy yes The frequency of the TT genotype was higher in those patients who were "good responders" to anti-TNF therapy, as compared to those who were "poor and nonresponders". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.06). Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CC + CT. 23057546 1444687090
TNF rs1799964 CC + CT lansoprazole efficacy no No significant difference in the percentage of patients who failed Helicobacter pylori (H. pylori) treatment were seen between the two genotype groups. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Genotypes CC + CT are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype TT. 16815316 1183680064
TNF rs1800610 GG rituximab efficacy no No significant association was seen between genotype and whether a patient was a "responder" or a "non-responder". "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Please note that this SNP was referred to as rs80267959, but was merged with rs1800610 in dbSNP. Genotype GG is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 22129793 982047122
TNF rs1800629 GG rituximab efficacy no No significant association was seen between genotype and whether a patient was a "responder" or a "non-responder". "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Genotype GG is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AG. 22129793 982047080
TNF rs1800629 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689715
TNF rs1800629 AG + GG adalimumab efficacy yes Response was defined as a DAS28 improvement of >=1.2 in some studies; other studies defined response using the ACR20. An ACR20 response corresponds to a decrease of at least 20% in the number of tender joints and the number of swollen joints, and an improvement of 20% in at least three of the following: the patient's assessment of pain, the patient's global assessment of disease status, the physician's global assessment of disease status, the patient's assessment of physical function, and C reactive protein. Genotypes AG + GG is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype AA. 22760475 1183703414
TNF rs1800629 GG etanercept efficacy yes A greater percentage of patients with the GG genotype were responders to treatment as compared to the AG genotype after 6 months and 1 year of treatment. Response assessed according to the Disease Activity Score in 28 joints (DAS28), where response was an improvement of >1.2. Additionally, those with the GG genotype had a higher mean DAS28 score improvement at 6 months, though this was a non-significant p-value. However, those with the GG genotype had a significantly higher mean DAS28 score improvement after 1 year of treatment. The authors note that 13 patients had received infliximab previously without success, which may have induced a bias in the study. Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG. 18050183 1444668552
TNF rs1800629 GG etanercept efficacy yes When this genotype is combined with the rs1800896 CC genotype. Those with the GG-CC combination genotype were more likely to be responders to treatment, as compared to those with any other combination of genotypes. However, no significant difference in genotype frequencies was seen between responders and non-responders when considering the rs1800629 or 1800896 SNPs alone. Responders defined using the American College of Rheumatology (ACR) response criteria and response criteria based on the modified disease activity score (DAS)28 index. Non-responders failed to fulfill both these criteria. Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 12759288 1444668176
TNF rs1800629 GG adalimumab efficacy no No significant difference in genotype frequencies was seen between those who were responders to treatment and those who were non-responders. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation. Genotype GG is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 17673491 1444693775
TNF rs1800629 GG infliximab efficacy no At 30 weeks of treatment. Response to treatment assessed using the American College of Rheumatology (ACR) 50 criteria. Good responders defined as >=50% improvement and poor responders <=20% improvement using ACR50. No significant difference in the percentage of patients defined as having an ACR50 response was seen between those with the GG genotype and those with the AA or AG genotype. Additionally, no significant results were seen when considering ACR20 or ACR70 response, or mean decrease in Disease Activity Score in 28 joints (DAS28), between the genotypes. Genotype GG is not associated with response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 18438841 1444668588
TNF rs1800629 GG adalimumab efficacy yes After 24 weeks of treatment, a greater percentage of those with the GG genotype were were responders to treatment, as compared to those with the AG genotype. Response classified according to the Disease Activity Score in 28 joints (DAS28). Additionally, those with the GG genotype had a greater DAS28 score improvement as compared to those with the AG genotype. No significant results were seen at week 8 or week 16 for either parameter, or when considering improvement using the American College of Rheumatology (ACR) definition at week 8, 16 or 24. Genotype GG is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotype AG. 17343250 1444668512
TNF rs1800629 AG + GG etanercept efficacy yes Patients with the AG and GG genotype had a greater decrease in Disease Activity Score in 28 joints (DAS28) between baseline and 6 months of treatment, as compared to those with the AA genotype. Linear regression analysis, adjusted for baseline DAS28, among other factors. Additionally, patients with the AG and GG genotype were also more frequent in the group classified as having a "good" response according to the EULAR criteria, as compared to those with the AA genotype. Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA. 18713756 1444668728
TNF rs1800629 AG Tumor necrosis factor alpha efficacy no No significant difference in the frequency of the genotypes was seen between patients who were classified as "good responders" and those who were classified as "poor and nonresponders". Poor responders were classified as those who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 20. Good responders were classified as those who fulfilled the ASAS 40, 50 and 70. Nonresponders were classified as those who failed to show any improvement as per the ASAS criteria. Note that this allele was significantly associated with incidence of ankylosing spondylitis (p = 0.0093). Additionally, note that no significant results were seen when comparing genotype frequencies between nonresponders and responders (poor and good responders combined; p=0.6). Genotype AG is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotype GG. 23057546 1444687074
TNF rs1800629 GG infliximab efficacy yes Good responders defined as patients whose disease activity score in 28 joints (DAS28) score improved by at least 1.2 at week 22 as compared to their DAS28 score before first infusion (EULAR criteria). Patients with the GG genotype were more likely to be good responders to infliximab treatment as compared to those with the AA or AG genotype. Additionally, those with the GG genotype had a higher mean DAS28 improvement as compared to those with the AA or AG genotype after 22 weeks. Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. 12847678 1444668242
TNF rs1800629 GG adalimumab efficacy yes Response assessed after 24 weeks of treatment using the Bath Ankylosing Spondylitis Activity Index (BASDAI). Good response was a BASDAI improvement of >50% from baseline, moderate response an improvement of >=20% and <=50%, and non-response an improvement of <20%. No patients with the AA genotype were present in the population. Patients with the GG genotype had a larger improvement in BASDAI score (3.30 +/- 1.52) as compared to those with the AG genotype (1.21 +/- 0.39). Genotype GG is associated with increased response to adalimumab or infliximab in people with Spondylitis, Ankylosing as compared to genotype AG. 16720636 1444668437
TNF rs4248158 CC infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype CC is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes CT + TT. 22960943 1183689675
TNF rs4987086 GG infliximab efficacy no No association between this SNP and IL1B or TNF serum concentrations in patients with Crohn's Disease or ulcerative colitis was found. Similarly, no association between this SNP and response to infliximab was found. Genotype GG is not associated with decreased response to infliximab in people with Colonic Diseases, Functional as compared to genotypes AA + AG. 22960943 1183689679